drugset / Trial / NCT07227922

Clofutriben Pharmacokinetics in Patients With Impaired Renal Function

NCT07227922

Phase 1 Recruiting 16 enrolled Sparrow Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.

Timeline

Start
2025-11-30
Primary completion
2026-04-30
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject clofutriben Small molecule 12 mg Oral

Indications

No indication recorded.